- Home
- DRRX vs ATRA Comparison
DRRX vs ATRA Comparison
Compare DRRX & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRRX
- ATRA
- Stock Information
- Founded
- DRRX 1998
- ATRA 2012
- Country
- DRRX United States
- ATRA United States
- Employees
- DRRX N/A
- ATRA N/A
- Industry
- DRRX Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DRRX Health Care
- ATRA Health Care
- Exchange
- DRRX Nasdaq
- ATRA Nasdaq
- Market Cap
- DRRX 59.3M
- ATRA 67.9M
- IPO Year
- DRRX 2000
- ATRA 2014
- Fundamental
- Price
- DRRX $1.92
- ATRA $12.05
- Analyst Decision
- DRRX Hold
- ATRA Strong Buy
- Analyst Count
- DRRX 1
- ATRA 3
- Target Price
- DRRX N/A
- ATRA $21.00
- AVG Volume (30 Days)
- DRRX 487.4K
- ATRA 50.7K
- Earning Date
- DRRX 08-12-2025
- ATRA 08-11-2025
- Dividend Yield
- DRRX N/A
- ATRA N/A
- EPS Growth
- DRRX N/A
- ATRA N/A
- EPS
- DRRX N/A
- ATRA 0.56
- Revenue
- DRRX $1,657,000.00
- ATRA $188,667,000.00
- Revenue This Year
- DRRX N/A
- ATRA N/A
- Revenue Next Year
- DRRX $673.00
- ATRA N/A
- P/E Ratio
- DRRX N/A
- ATRA $21.39
- Revenue Growth
- DRRX N/A
- ATRA 202.41
- 52 Week Low
- DRRX $0.48
- ATRA $5.01
- 52 Week High
- DRRX $2.64
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- DRRX 78.08
- ATRA 55.38
- Support Level
- DRRX $1.86
- ATRA $11.86
- Resistance Level
- DRRX $1.96
- ATRA $12.76
- Average True Range (ATR)
- DRRX 0.04
- ATRA 0.83
- MACD
- DRRX -0.04
- ATRA -0.02
- Stochastic Oscillator
- DRRX 60.00
- ATRA 53.39
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).